Outcomes in<unk>  have improved significantly since treatment with rituximab has become more common. In one published case series from an experienced center, observed survival in a cohort of HIV patients with<unk>  was 94% at 2 years and 90% at 5 years.
HHV-8-associated MCD
Cytomegalic inclusion body disease
Epstein–Barr virus–associated lymphoproliferative diseases
AIDS-related lymphoma
Fibrin-associated diffuse large B-cell lymphoma
Tuberculosis in relation to HIV
Hepatitis C and HIV coinfection
Epstein–Barr virus infection